Elesclomol (also known as STA-4783), originally identified in a cell-based phenotypic screen for proapoptotic activity, is a novel small-molecule that potently induces apoptosis of cancer cells through the rapid generation of reactive oxygen species (ROS) and the induction of unmanageable levels of oxidative stress. Elesclomol exhibits autitumor activity against a broad spectrum of types of cancer cell in human tumor xengograft models due to its excessive ROS production and elevated levels of oxidative stress leading to the death of cancer cells.? Elesclomol is currently being studies as a novel cancer therapeutic, in which it has demonstrated ability to prolong progression-free survival in study subjects.
Reference
[1].Ronald K. Blackman, Kahlin Cheung-Ong, Marinella Gebbia, David A. Proia, Suqin He, Jane Kepros, Aurelie Jonneaux, Philippe Marchetti, Jerome Kluza, Patricia E. Rao, Yumiko Wada, Guri Giaever, Corey Nislow. Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS ONE 2012; 7(1): e29798
[2].Jessica R. Kirshner, Suqin He, Vishwasenani Balasubramanyam, Jane Kepros, Chin-Yu Yang, Mei Zhang, Zhenjian Du, James Barsoum, and John Bertin. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 2008; 7:2319-2327
Elesclomol（也称为 STA-4783）最初是在基于细胞的表型筛选中发现的促凋亡活性,是一种新型小分子,可通过快速产生活性氧 (ROS) 有效诱导癌细胞凋亡以及难以控制的氧化应激水平的诱导。 Elesclomol 在人类肿瘤异种移植模型中表现出针对多种类型癌细胞的抗肿瘤活性,这是由于其过量的 ROS 产生和升高的氧化应激水平导致癌细胞死亡。 Elesclomol 目前正在作为一种新型癌症治疗药物进行研究,已证明它能够延长研究对象的无进展生存期。